Waseem Allabban, MD
Rheumatology · Chandler, AZNPI 1972704427
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,216 of the $10,431 with a category attached, or 78.8%. 37 manufacturers reported payments, led by UCB, Inc. at 26.9% of the total.
Across 459 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$3K
- Amgen$2K
- AbbVie$1K
- Johnson & Johnson$772
- Pfizer$723
- GSK$532
- plus $3K from 31 others
What the payments were for
- Consulting fees$2,07020%
- Travel & lodging$250%
- Food & beverage$8,21679%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 23 | $2,804 |
| Amgen(2 entities) | 122 | $1,747 |
| AbbVie | 65 | $1,196 |
| Johnson & Johnson(2 entities) | 55 | $772 |
| Pfizer | 36 | $723 |
| GSK | 31 | $532 |
| Lilly USA, LLC | 18 | $405 |
| Radius Health, Inc. | 18 | $379 |
| Mallinckrodt Hospital Products Inc. | 10 | $302 |
| E.r. Squibb & Sons, L.L.C. | 12 | $198 |
| Novartis | 9 | $181 |
| Actelion Pharmaceuticals US, Inc. | 6 | $152 |
| Genentech USA, Inc. | 8 | $137 |
| Sanofi | 4 | $77 |
| Boehringer Ingelheim | 4 | $75 |
| AstraZeneca(2 entities) | 4 | $69 |
| Almatica Pharma LLC | 3 | $59 |
| Fresenius Kabi USA, LLC | 2 | $58 |
| Gilead | 2 | $54 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| Organon | 3 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $43 |
| Octapharma USA, Inc. | 1 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Aurinia Pharma U.S., Inc. | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $34 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $18 |
| Sebela Pharmaceuticals Inc. | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
$10,431 in reported general payments places this provider in the 65th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 248 | $9,382 |
| Mycophenolate Mofetil | 40 | $4,423 |
| MethotrexateMethotrexate Sodium | 194 | $3,976 |
| Sulfasalazine DrSulfasalazine | 71 | $3,048 |
| Cevimeline Hcl | 13 | $2,114 |
| Prednisone | 258 | $2,022 |
| Colchicine | 40 | $1,749 |
| Leflunomide | 31 | $1,235 |
| Sulfasalazine | 26 | $1,010 |
| Diclofenac Sodium | 11 | $821 |
| Folic Acid | 46 | $480 |
| Ibandronate Sodium | 20 | $423 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 16 | $360 |
| Allopurinol | 41 | $331 |
| Alendronate Sodium | 36 | $283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Colchicine | $43 | $1,74940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Chandler
- Amer Al-KhoudariChandler$369K
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Joy SchechtmanPeoria$860K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Andrew SharobeemGlendale$231K
- Paul HowardScottsdale$124K
- Sherif NasefYuma$111K
- Michael MaricicTucson$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.